These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 23821693)

  • 1. Successful treatment of refractory autoimmune hepatitis with rituximab.
    D'Agostino D; Costaguta A; Álvarez F
    Pediatrics; 2013 Aug; 132(2):e526-30. PubMed ID: 23821693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab for refractory autoimmune hepatitis: a case report.
    Al-Busafi SA; Michel RP; Deschenes M
    Arab J Gastroenterol; 2013 Sep; 14(3):135-8. PubMed ID: 24206745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy.
    Burak KW; Swain MG; Santodomingo-Garzon T; Lee SS; Urbanski SJ; Aspinall AI; Coffin CS; Myers RP
    Can J Gastroenterol; 2013; 27(5):273-80. PubMed ID: 23712302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and prospective pharmacotherapy for autoimmune hepatitis.
    Czaja AJ
    Expert Opin Pharmacother; 2014 Aug; 15(12):1715-36. PubMed ID: 24961409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Experience with rituximab treatment (monoclonal antibodies to B-lymphocyte CD20 receptors) of Wegener's granulomatosis patients with renal impairment].
    Novikov PI; Krivosheev OG; Semenkova EN
    Ter Arkh; 2011; 83(11):70-6. PubMed ID: 22312891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases.
    El-Hallak M; Binstadt BA; Leichtner AM; Bennett CM; Neufeld EJ; Fuhlbrigge RC; Zurakowski D; Sundel RP
    J Pediatr; 2007 Apr; 150(4):376-82. PubMed ID: 17382113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab and its use in autoimmune bullous disorders.
    Daniel BS; Murrell DF; Joly P
    Dermatol Clin; 2011 Oct; 29(4):571-5. PubMed ID: 21925000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current therapy of the pemphigus group.
    Kasperkiewicz M; Schmidt E; Zillikens D
    Clin Dermatol; 2012; 30(1):84-94. PubMed ID: 22137231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab in refractory pemphigus vulgaris.
    Sorce M; Aricò M; Bongiorno MR
    Dermatol Ther; 2008 Jul; 21 Suppl 1():S6-9. PubMed ID: 18727815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of rituximab treatment in children with primary glomerulonephritis.
    Zachwieja J; Silska M; Ostalska-Nowicka D; Soltysiak J; Lipkowska K; Blumczynski A; Musielak A
    J Nephrol; 2012; 25(6):1060-6. PubMed ID: 22322817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab for autoimmune blistering diseases: recent studies, new insights.
    Lunardon L; Payne AS
    G Ital Dermatol Venereol; 2012 Jun; 147(3):269-76. PubMed ID: 22648328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid.
    Myers RP; Swain MG; Lee SS; Shaheen AA; Burak KW
    Am J Gastroenterol; 2013 Jun; 108(6):933-41. PubMed ID: 23649186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Refractory disease in antineutrophil cytoplasmic antibodies associated vasculitis.
    Rutgers A; Kallenberg CG
    Curr Opin Rheumatol; 2012 May; 24(3):245-51. PubMed ID: 22410545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of everolimus in the treatment of autoimmune hepatitis related to anti-hepatitis C virus therapy after liver transplant: three case reports.
    Casanovas T; Argudo A; Peña-Cala MC
    Transplant Proc; 2011; 43(6):2233-6. PubMed ID: 21839242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience.
    Kanzler S; Löhr H; Gerken G; Galle PR; Lohse AW
    Z Gastroenterol; 2001 May; 39(5):339-41, 344-8. PubMed ID: 11413913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effectiveness and safety of rituximab in pemphigus vulgaris].
    Alonso Sánchez A; García Rodríguez S; López Avila A; Rabell Iñigo S
    Farm Hosp; 2010; 34(2):98-9. PubMed ID: 20304370
    [No Abstract]   [Full Text] [Related]  

  • 17. Refractory childhood pemphigoid successfully treated with rituximab.
    Fuertes I; Luelmo J; Leal L; Romaní J; Sánchez S; Mascaró JM
    Pediatr Dermatol; 2013; 30(5):e96-7. PubMed ID: 23278674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).
    Kong HH; Prose NS; Ware RE; Hall RP
    Pediatr Dermatol; 2005; 22(5):461-4. PubMed ID: 16191003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Childhood pemphigus vulgaris successfully treated with rituximab.
    Kanwar AJ; Sawatkar GU; Vinay K; Hashimoto T
    Indian J Dermatol Venereol Leprol; 2012; 78(5):632-4. PubMed ID: 22960821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab in dermatology.
    España A; Ornilla E; Panizo C
    Actas Dermosifiliogr; 2013 Jun; 104(5):380-92. PubMed ID: 23665436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.